RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
0.5440
+0.0050 (0.93%)
Oct 12, 2026, 11:34 AM EDT - Market open
RedHill Biopharma Revenue
In the year 2025, RedHill Biopharma had annual revenue of $286.00K. That makes RedHill Biopharma the 45,117th largest company in the world by revenue and 6,515th in the United States.
Revenue (ttm)
$286.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
3.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 286.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
| Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
| Dec 31, 2018 | 8.36M | 4.35M | 108.63% |
| Dec 31, 2017 | 4.01M | 3.91M | 3,867.33% |
| Dec 31, 2016 | 101.00K | 98.00K | 3,266.67% |
| Dec 31, 2015 | 3.00K | -7.01M | -99.96% |
| Dec 31, 2014 | 7.01M | 7.00M | 58,350.00% |
| Dec 31, 2013 | 12.00K | -4.00K | -25.00% |
| Dec 31, 2012 | 16.00K | -7.00K | -30.43% |
| Dec 31, 2011 | 23.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 46.18M |
| Sunshine Biopharma | 35.35M |
| IM Cannabis | 32.25M |
| Sonoma Pharmaceuticals | 21.92M |
| cbdMD | 20.93M |
| InMed Pharmaceuticals | 4.94M |
| Akanda | 662.47K |
| Gelteq | 314.70K |
RDHL News
- 11 days ago - RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results - PRNewsWire
- 12 days ago - RedHill Biopharma Earnings release: H1 2026 - Filings
- 4 weeks ago - RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio - TipRanks
- 5 weeks ago - RedHill Sells its Talicia® H. pylori Drug Business to Apotex in $18M Deal to Fuel Growth - TipRanks
- 5 weeks ago - RedHill acquires exclusive commercialization rights to Rebyota, Clenpiq for $12M - TheFly
- 5 weeks ago - RedHill announces acquisition of commercialization rights to Rebyota, Clenpiq - TheFly
- 5 weeks ago - RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® - PRNewsWire
- 6 weeks ago - Why Is Penny Stock RedHill Biopharma (RDHL) Up 103% Today? - TipRanks